Zealand Pharma reports positive Phase 2 results for petrelintide in type 2 diabetes
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)